

Acronyms and abbreviations

ACIM	Action against Counterfeit & Illicit Medicines
AED	Advance electronic data
AMR	Antimicrobial resistance
ASOP EU	Alliance for Safe Online Pharmacy in the EU
ASOP Global	Alliance for Safe Online Pharmacies - Global
ATD	Anti-tamper device
CBP	US Customs and Border Protection
DEA	Drug Enforcement Administration
DG TAXUD	European Commission's Directorate-General for Taxation and Customs Union
EAASM	European Alliance for Access to Safe Medicines
EU	European Union
EUIPO	European Union Intellectual Property Office
FDA	Federal Drug Administration
FMD	Falsified Medicines Directive
FTZ	Free trade zone
ICANN	Internet Corporation for Assigned Names and Numbers
ICC	International Chamber of Commerce
ICE	US Immigration and Customs Enforcement
IFPMA	International Federation of Pharmaceutical Manufacturers & Associations
IMF	International mail facility
INTERPOL	International Criminal Police Organization
IOM	Institute of Medicines of the National Academies
IP	Intellectual property
IPR	Intellectual property rights
IRACM	International Institute of Research against Counterfeit Medicines
MHRA	Medicines and Healthcare products Regulatory Agency
NAPB	National Association of Boards of Pharmacy

NMRA	National or regional Medicines Regulatory Authority
OCG	Organised crime groups
OECD	Organisation for Economic Co-operation and Development
OTC	Over-the-counter
PPC	Pay-per-click
PSI	Pharmaceutical Security Institute
R&D	Research and development
RCAP-e	Relative comparative advantage for production
RCAT-e	Relative comparative advantage for being a transit point
RPSGB	Royal Pharmaceutical Society of Great Britain
TRIPS	Agreement on Trade-Related Aspects of Intellectual Property Rights
UNICEF	United Nations International Children's Emergency Fund
UNICRI	United Nations Interregional Crime and Justice Research Institute
UNIDO	United Nations Industrial Development Organization
UNODC	United Nations Office on Drugs and Crime
VIPPS	Verified Internet Pharmacy Practice Sites
WCO	World Customs Organization
WHO	World Health Organization
WIPO	World Intellectual Property Organization
WTO	World Trade Organization

Table of contents

Preface	3
Foreword	4
Acknowledgements	5
Acronyms and abbreviations	6
Executive Summary	10
1 Introduction	14
Notes	15
References	15
2 Counterfeit pharmaceuticals: scope and data	16
Definition and scope	16
Data	18
Notes	20
References	21
3 Industry overview	22
International trade in pharmaceutical products	23
IP intensity of the pharmaceutical industry	25
Notes	26
References	27
4 Mapping the scale of the fake pharmaceutical challenge	28
Scale of the problem	28
Types of counterfeit pharmaceuticals	30
Which IP right holders are most affected?	32
Trade routes for counterfeit pharmaceuticals	33
Producers and transit points	36
Notes	40
References	40
5 The supply chain: marketing, transport and distribution	41
Modes of transport	42
Sales channels	45

Free trade zones	48
Notes	50
References	50
6 The push factors behind counterfeit pharmaceuticals	52
Profitability	53
Low risk of detection	53
Low risk of prosecution	54
Weak penalties	54
References	55
7 Impact of counterfeit medicines	56
Impact on individuals	57
Impact on producers	57
Impact on governments	60
Economy-wide effects	61
Notes	64
References	65
8 Efforts to combat counterfeit pharmaceuticals	67
INTERPOL	67
World Customs Organization	69
World Health Organization	70
Legislative measures	72
Notes	74
References	75
9 Concluding remarks	76
Next steps	77
Annex A. Data and methodology	78
The data	78
Construction of GTRIC-e for pharmaceuticals	80
Methodology to identify producers from transit points of counterfeit pharmaceuticals	82
Notes	84
References	84
Annex B. Additional Tables	85
Tables	
Table 3.1. Largest 50 pharmaceutical companies, by country of headquarters, 2017	23
Table 3.2. Size of the largest pharmaceutical companies, 2017	23
Table 3.3. R&D intensity in the 50 largest pharmaceutical firms, 2017	26
Table 4.1. The 10 economies most likely to be a provenance of counterfeit pharmaceutical products	35
Table 4.2. Top ten economies most likely to be a provenance of counterfeit pharmaceuticals imported into the EU	35
Table 4.3. Main producing economies and transit points for counterfeit pharmaceutical products and medicines traded worldwide, 2014-2016	37
Table 4.4. Main producing economies and transit points for counterfeit pharmaceutical products and medicines exported to the EU, 2014-2016	38

Table 4.5. Top ten countries for the number of arrests of individuals engaged in manufacturing counterfeit medicines, 2018	39
Table 6.1. Framework for assessing the attractiveness of counterfeiting pharmaceuticals	52
Table 6.2. Maximum incarceration for trademark infringement and narcotics trafficking	54
Table 6.3. Selected features of trademark regimes in Brazil, China, India, Russian Federation and South Africa, 2016	55
Table 7.1. Pharmaceutical cases possibly involving organised crime groups, 2013	62
Table 8.1. Operation Pangea 2008-2018	68
Table 8.2. Selected Interpol operations involving pharmaceutical products, 2018	68
Table 8.3. Actions to implement the WHO's "prevent, detect and respond" approach in tackling substandard and falsified medicines	71
Table B.1. Description of the HS 30 product category, pharmaceutical products	85
Table B.2. RCAP indices for counterfeit pharmaceuticals, 2014-2016	88
Table B.3. RCAT indices for pharmaceuticals, 2016	89

Figures

Figure 3.1. Top 20 exporters of pharmaceuticals, 2014-2016	24
Figure 3.2. Top 20 importers of pharmaceuticals, 2014-16	24
Figure 4.1. Top product categories counterfeit or pirated, 2014-2016	29
Figure 4.2. Number of total incidents by year, 2014-18	30
Figure 4.3. Most counterfeit types of pharmaceuticals seized by customs, 2014-2016	31
Figure 4.4. Top five therapeutic categories reported in counterfeiting incidents	31
Figure 4.5. Top 15 pharmaceutical-producing economies, 2016	32
Figure 4.6. Top provenance economies for counterfeit pharmaceuticals, 2014-2016	33
Figure 4.7. Top provenance economies of counterfeit pharmaceuticals imported into the EU, 2014-2016	34
Figure 4.8. Percentage of arrests by crime, 2018	38
Figure 5.1. Transport modes for counterfeit pharmaceuticals	42
Figure 5.2. Transport modes for counterfeit pharmaceuticals exported to EU economies	43

Boxes

Box 2.1. Diversion and theft of pharmaceuticals	18
Box 2.2. Pharmaceutical Security Institute (PSI)	20

Follow OECD Publications on:



http://twitter.com/OECD_Pubs


<http://www.facebook.com/OECDPublications>


<http://www.linkedin.com/groups/OECD-Publications-4645871>


<http://www.youtube.com/oecdilibrary>


<http://www.oecd.org/oecddirect/>



From:
Trade in Counterfeit Pharmaceutical Products

Access the complete publication at:

<https://doi.org/10.1787/a7c7e054-en>

Please cite this chapter as:

OECD/European Union Intellectual Property Office (2020), "Acronyms and abbreviations", in *Trade in Counterfeit Pharmaceutical Products*, OECD Publishing, Paris.

DOI: <https://doi.org/10.1787/940d052e-en>

This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries.

This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. Extracts from publications may be subject to additional disclaimers, which are set out in the complete version of the publication, available at the link provided.

The use of this work, whether digital or print, is governed by the Terms and Conditions to be found at <http://www.oecd.org/termsandconditions>.